The Halogenated Organics Subcommittee evaluated the animal evidence for carcinogencity of chlorobenzene to be 'inadequate' under EPA's new guidelines based on the lack of a statistically significant increase in the incidence of tumors in female mice, male mice and female rats, and on the basis of the perception of a diminished biologic significance of reported malignant neoplastic nodules of the liver in the highest dose-treated male rats. The evidence would place chlorobenzene into the overall weight-of-the-evidence category D (not classified).